Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations

This study is to retrospectively evaluate the prevalence ofMYD88 andCD79B mutations and the clinicopathologic characteristics of patients with primary diffuse large B cell lymphoma (DLBCL) of the female genital tract and breast. The characteristics, treatments, and outcomes of 19 patients diagnosed with primary DLBCL of the female genital tract and breast, who had formalin-fixed and paraffin-embedded tissues obtained from diagnostic samples diagnosed between January 2004 and June 2016, were analyzed retrospectively. Nineteen female patients (7 with primary breast and 12 with primary female genital tract DLBCL) were included in this retrospective study. Eleven patients (57.9%) carried aMYD88 mutation, including 10 withMYD8 L265P and 1 with theMYD88 L265S mutation. Seven patients (36.8%) harbored aCD79B mutation, which included two cases withCD79B Y196H, two cases withCD79B Y196N, one case withCD79B Y196D, one case withCD79B Y196F, and one case withCD79B Y196X. Four cases had bothMYD88 andCD79B mutations. The clinicopathologic parameters, progression-free survival (PFS), and overall survival (OS) of theMYD88 mutation-carrying group were not significantly different from those of theMYD88 wild-type group except for higher LDH levels. Six patients received cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP), while 13 patients received rituximab plus CHOP, and 13 patients received central nervous system prophylaxis. The median OS and PFS were 73 and 56  months, res...
Source: Annals of Hematology - Category: Hematology Source Type: research